TG Therapeutics Inc. (TGTX)
| Bid | 31.05 |
| Market Cap | 4.85B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.1 |
| PE Ratio (ttm) | -311.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 31.3 |
| Volume | 1,519,972 |
| Avg. Volume (20D) | 2,213,974 |
| Open | 30.83 |
| Previous Close | 30.71 |
| Day's Range | 29.73 - 31.57 |
| 52-Week Range | 12.84 - 36.84 |
| Beta | undefined |
About TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
Analyst Forecast
According to 6 analyst ratings, the average rating for TGTX stock is "Buy." The 12-month stock price forecast is $41.5, which is an increase of 33.31% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
TG Therapeutics: Entering 2025 With Increased Investor ExpectationsTG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sal...
1 month ago · seekingalpha.com
TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term CatalystTG Therapeutics is already marketing an IV infusion of Briumvi, but is also developing a subcutaneous form, which could help it compete with other multiple sclerosis drugs. The company expects to repo...
